medac and Clinigen strengthen APAC cooperation
medac and Clinigen expand their collaboration in the APAC region – six key therapies will be exclusively marketed and distributed.
Elinzanetant Significantly Reduces Hot Flashes in Breast Cancer Patients
Results from the OASIS-4 study show that elinzanetant significantly reduces the frequency and severity of hot flashes in HR+ breast cancer patients – offering a potential new hormone-free treatment option.
Gilead and Global Fund Expand HIV Prevention Access
Gilead will supply lenacapavir at no profit to up to two million people in high-incidence, low-income countries through a partnership with the Global Fund.
Bayer Looks to Supreme Court in Glyphosate Dispute
Bayer welcomes the U.S. Supreme Court’s decision to involve the Solicitor General in the Durnell case – a potential turning point in the glyphosate litigation.
Araris Biotech Wins Strüngmann Award 2025
Araris Biotech has been awarded the Strüngmann Award 2025 for its groundbreaking ADC technology – a milestone for targeted cancer therapies.
Zeller relaxes with a fear-focused twist
Max Zeller Söhne AG draws attention to zeller entspannung with a bold campaign centered around rare phobias. The herbal remedy is repositioned as a solution for stress and anxiety.
Torrent takes over JB Pharma – billion-euro deal in the pharmaceutical sector
Torrent Pharma acquires a majority stake in JB Chemicals & Pharmaceuticals from KKR for over INR 25,000 crore and announces a subsequent merger. The deal significantly strengthens Torrent's market presence in India and globally.
Innovation und Networking: expopharm 2025 unites the industry
From September 16–18, 2025, expopharm in Düsseldorf will bring together new exhibitors, forward-looking formats, and a strong network for the pharmacy and healthcare sector.
Healthcare marketing 2025: efficient and data-driven
In 2025, marketers will increasingly rely on smart targeting and omnichannel concepts to achieve maximum impact with shrinking budgets.
BioNTech Acquires CureVac: Focus on mRNA for Cancer
BioNTech announces the full acquisition of CureVac to significantly expand its mRNA research and cancer therapy platform. The transaction strengthens Germany’s role in the global biotech landscape.
Merck Acquires SpringWorks for $3.4 Billion
Merck drives growth in its Healthcare business with the $3.4 billion acquisition of SpringWorks Therapeutics, expanding into rare tumor therapies.
Free Blood Test for Cats: Take Precaution Now!
Many cats suffer from undetected diseases. Boehringer Ingelheim now offers free blood tests for cats nationwide – redeemable with a voucher until August 15, 2025.
Risks of Automatic Substitution of Biopharmaceuticals
Automatic substitution of biopharmaceuticals poses major risks to patient care and Germany’s pharmaceutical sector, leading industry associations warn.
Pneumococcal Infections on the Rise – Vaccination Rates Still Low
While the flu wave has peaked, pneumococcal infections are on the rise. Older people are especially at risk – vaccination offers effective protection.
Vetter Recognized Again as Best Managed Company
Vetter has once again been recognized as a “Best Managed Company” in its anniversary year. The award honors the company's strategic focus and sustainable management approach.
Pharmacy and Science: A Glimpse into the Future
INTERPHARM 2025 in Stuttgart delivers cutting-edge insights into autoimmune diseases, skin health, eye care, and the future of healthcare. Discover the highlights now!
Health Insurers Warn: Premium Surcharges to Rise Again
Germany’s public health insurers warn of rising premium surcharges. Hospital stays, medication costs, and more severe illnesses are driving up expenses.
EU reviews producer responsibility in wastewater directive
The EU Commission is reviewing the costs and impacts of extended producer responsibility in the Urban Wastewater Directive. Pharma Germany welcomes the move.
Reimbursable Medications for Smoking Cessation Approved
Patients with severe tobacco addiction can now receive reimbursable medications like nicotine or varenicline as part of certified cessation programs.
ITM Secures Up to $262.5M in Financing from Blue Owl
ITM secures up to $262.5M from Blue Owl to support the commercialization of ITM-11 and expand its radiopharmaceutical pipeline.